Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 28.14% | -2.16% | 25.89% | 14.65% | 13.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.14% | -2.16% | 25.89% | 14.65% | 13.59% |
| Cost of Revenue | 6.91% | -3.08% | 13.44% | 27.77% | 2.85% |
| Gross Profit | 161.90% | 5.36% | 37.29% | -63.20% | 41.27% |
| SG&A Expenses | 1.15% | -1.15% | 7.39% | 7.80% | 7.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.09% | -2.48% | 11.71% | 21.86% | 4.41% |
| Operating Income | 30.56% | 2.80% | 7.38% | -29.47% | 7.19% |
| Income Before Tax | 20.18% | -22.67% | 3.86% | -34.78% | 12.80% |
| Income Tax Expenses | 0.00% | 0.00% | 126.56% | 188.12% | 16.55% |
| Earnings from Continuing Operations | 20.00% | -22.52% | 3.49% | -35.12% | 12.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.00% | -22.52% | 3.49% | -35.12% | 12.61% |
| EBIT | 30.56% | 2.80% | 7.38% | -29.47% | 7.19% |
| EBITDA | 32.32% | 2.24% | 7.33% | -31.69% | 7.91% |
| EPS Basic | 22.67% | -17.28% | 7.56% | -29.33% | 23.19% |
| Normalized Basic EPS | 22.85% | 1.72% | 8.00% | -28.83% | 20.94% |
| EPS Diluted | 22.67% | -17.28% | 7.56% | -29.33% | 23.19% |
| Normalized Diluted EPS | 22.85% | 1.72% | 8.00% | -28.83% | 20.94% |
| Average Basic Shares Outstanding | 3.45% | 4.47% | 4.41% | 4.48% | 13.77% |
| Average Diluted Shares Outstanding | 3.45% | 4.47% | 4.41% | 4.48% | 13.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |